Non Small Cell Lung Cancer (NSCLC) Therapeutics in Asia-Pacific Markets is Expected to Cross Over $2 Billion By 2019

The non small cell lung cancer (NSCLC) market is Asia Pacific region was valued over $1 billion in 2012. This industry is projected to grow at a compound annual growth rate of over 6% and is expected to cross over $2 billion by 2019.

Rising number of NSCLC incident cases, launch of promising therapies and escalating geriatric population are the major drivers for NSCLC market. The launch of innumotherapies and premium-priced novel antibodies in the primary and the next lines of therapy will drive the market.

It includes nivolumab, beehringer ingelheim’s gilotriff, Bristol-myers squibb’s Yervoy and Eli Lilly’s necitumumab.  Although, expected pricing restrictions in china, the implementation of a price ceiling in vital drugs and dominance of genetic drugs in India could hinder the market demand for NSCLC in APAC regions.

A defined genetic mutation being targeted that directs the progression of lung cancer is the effective treatment process in lung cancer. Analyzing of DNA of lung cancer cells os being done by several number of cancer centers.

Discovery of more genetic mutations owing to the rising genomic information has provided new opportunities to the treatment mainly at those genetic mutations. This is anticipated to positively impact the NSCLC Therapeutics in Asia-Pacific Markets.

NSCLC is highly expected to metastasize into the tissues and bones making it tough to identify and to treat the disease.  Furthermore, it accounts for over 90% of the all lung cancer cases. The market is undergoing high growth owing to the initiatives taken by government and its high population among the population.

Furthermore, Swift approvals are given by regulatory bodies by b NSCLC drugs.  On addition, this will result in new generation of drugs to introduce in the NSCLC industry positively affecting the NSCLC Therapeutics in Asia-Pacific Markets.

Sample Request:
http://www.radiantinsights.com/research/nsclc-therapeutics-in-asia-pacific-markets-to-2019-personalized-therapies-focus-on-untapped-segment-of-squamous-cell-carcinoma-to-expand-treatment-pool/request-sample

Table of Contents:
 
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Symptoms
2.2 Etiology
2.3 Pathophysiology
2.4 Co-morbidities and Complications
2.5 Diagnosis
2.6 Classification
2.7 Epidemiology
2.8 Prognosis and Disease Staging
2.9 Treatment Options
3 Marketed Products
3.1 Therapeutic Landscape
3.2 Comparative Efficacy and Safety